Elisabeth Krug, Ph.D.
Executive Director, Eli Lilly & Company
Elisabeth Krug, Ph.D. is listed as Executive Director, Eli Lilly & Company. Elisabeth is scheduled to speak at BPI West 2027 on 17 March 2027.
Compiled from published conference agendas; not yet confirmed by Elisabeth. Is this you? Claim this profile.
About
Dr. Elisabeth Krug is an Executive Director at Eli Lilly with over 30 years of experience in small and large molecule analytical development, spanning preclinical through BLA/NDA. A pharmaceutical biologist by training (University of Würzburg), she joined Lilly Hamburg in 1995 as an analytical scientist.After four years as a Black Belt, she earned her Master Black Belt in Six Sigma in 2010. She subsequently joined Lilly's large molecule analytical development group, including an interim assignment heading the bioassay development group. Throughout her career, Elisabeth has been responsible for defining and delivering the analytical control strategy supporting global regulatory submissions.
Upcoming
BPI West 2027 16 March 2027 – 18 March 2027
- Commercial Readiness Early On – What Does this Mean for Analytical Development? Speaker · 17 March 2027